The biotechnology industry comprises both established commercial-stage companies like Amgen Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Inc., and Regeneron Pharmaceuticals Inc., and smaller clinical-stage firms. While the larger companies generate profits from selling treatments, the clinical-stage companies rely on funding drug trials with hopes of approval. Investing in biotech can be challenging due to the binary nature of returns, where a stock can either soar on positive trial data or plummet on regulatory setbacks.
One way to mitigate risks and gain exposure to the industry’s overall growth is through biotech exchange-traded funds (ETFs). These ETFs provide a diversified approach, reducing the reliance on the success of individual companies. By investing in a basket of biotech firms, investors can benefit from the sector’s innovation and long-term structural shifts in healthcare. ETFs like the VanEck Vectors Biotech ETF (BBH) focus on large, established biotech companies, offering exposure to industry leaders like Amgen, Gilead, Vertex, and Regeneron.
For beginners in biotech investing, ETFs such as the iShares Nasdaq Biotechnology ETF (IBB) provide a stable option. IBB tracks the NYSE Biotechnology Index, with a concentration on larger, more stable companies, resulting in slightly lower volatility compared to the broader market. Similarly, the First Trust NYSE Arca Biotechnology Index Fund (FBT) offers exposure to biotech stocks using a fundamentals-based screening approach, selecting holdings based on revenue and research and development metrics.
Investors seeking a more specialized approach can consider ETFs like the iShares Biotechnology ETF (IBBQ) and the Invesco Dynamic Biotechnology & Genome ETF (PBE). IBBQ tracks the Nasdaq Biotechnology Index, offering exposure to biotech and pharmaceutical stocks listed on the Nasdaq exchange. On the other hand, PBE follows a multi-factor fundamentals-based approach to select biotech companies, leaning slightly towards smaller market-cap firms.
For those interested in genomics and biotechnology specifically, the Global X Genomics & Biotechnology ETF (GNOM) focuses on firms deriving at least 50% of their revenue from gene editing, genomic sequencing, genetic medicines, or computational genomics. This ETF includes mid-cap biotech companies like CRISPR Therapeutics AG and Illumina Inc., known for their innovations in gene-editing therapies and genomic sequencing technology.
In conclusion, investing in biotech ETFs provides a diversified and less risky approach to gaining exposure to the dynamic and impactful biotechnology sector. By choosing ETFs that align with their risk tolerance and investment goals, individuals can participate in the industry’s growth potential while minimizing the inherent risks associated with investing in individual biotech companies.
Key Takeaways:
– Biotech ETFs offer a diversified approach to investing in the biotechnology sector, reducing reliance on the success of individual companies.
– ETFs like BBH, IBB, and FBT provide exposure to established biotech firms, while IBBQ, PBE, and GNOM offer specialized approaches focusing on specific segments within the industry.
– By investing in biotech ETFs, investors can benefit from the industry’s innovation and long-term growth prospects while managing risks associated with clinical-stage biotech companies.
Tags: regulatory, biotech, clinical trials
Read more on wtop.com